SynthesisPloS one2025
Association between arsenic exposure and intrauterine growth restriction: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several observational studies have explored the link between arsenic (As) exposure and intrauterine growth restriction (IUGR). However, epidemiological findings have been inconsistent, with a wide range of reported heterogeneity. This study aims to systematically evaluate the association between As exposure and IUGR (SGA(Small for gestational age), PTB(Preterm birth), LBW(Preterm birth)) through a meta-analysis. We searched six databases-China National Knowledge Infrastructure, Wan Fang, VIP Database, PubMed, Web of Science, and Science Direct-for studies on As exposure and IUGR up to May 2024. After screening and data extraction, a comprehensive bias risk assessment was conducted using the Newcastle-Ottawa Scale (NOS), AHRQ (the assessment tool of the Agency for Healthcare Research and Quality), and NTP/OHAT (the assessment tool of the National Toxicology Program/Office of Health Assessment and Translation). Meta-analysis was conducted using random-effects models (I2 > 50%) or fixed-effects models (I2 < 50%) to estimate effect sizes. Subgroup analysis and meta-regression analysis were performed to identify the sources of heterogeneity. Publication bias was assessed using the Egger test, Begg test, and funnel plot. Eleven studies, including 2,183,652 participants from the Americas, Europe, Asia, and Africa, were analyzed. Results showed a significant association between As exposure and SGA (OR: 1.06, 95% CI: 1.00, 1.13), particularly in Asia (OR: 1.28, 95% CI: 1.10, 1.49). Maternal exposure to higher As levels (10-100 μg/L) was also significantly associated with SGA (OR: 1.25, 95% CI: 1.04, 1.50). Although PTB (OR: 1.03, 95% CI: 0.99, 1.07) and LBW (OR: 1.03, 95% CI: 0.97, 1.09) did not show overall significant associations, subgroup analyses revealed increased risks under specific conditions. As exposure at 1-10 μg/L significantly increased PTB risk (OR: 1.13, 95% CI: 1.06, 1.21), while exposure at 0-1 μg/L significantly increased LBW risk (OR: 1.13, 95% CI: 1.06, 1.21). This study supports a link between As exposure and increased IUGR risk, particularly SGA. Stricter public health policies are needed to reduce arsenic exposure during pregnancy. However, due to heterogeneity and potential publication bias, results should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.